Genfit S.A. (0QT6.IL)
| Previous close | 3.3075 |
| Open | 3.2250 |
| Bid | 3.1000 x 0 |
| Ask | 3.2550 x 0 |
| Day's range | 3.1702 - 3.2250 |
| 52-week range | 3.1150 - 4.9000 |
| Volume | |
| Avg. volume | 22,360 |
| Market cap | 158.351M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the health authorities by Ipsen, and a potential first milestone met before the end of 2023, and if approved, commercialization would trigger further milestone payments and royalty payments GENFIT’s leadership in ACLF is further strengthened, with now 5 complementary assets in development,
- Globe Newswire
GENFIT to Participate in Upcoming Investor Conferences
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 05, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences. Morgan Stanley 21st Annual Global Healthcare Conference Date: September 11-13, 2023Location: New York H.C. Wainwright 25th Annual Global Investment Confe
- Globe Newswire
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); August 10, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of new data on the clinical performance of NIS2+™ in older patients, for the detection of at-risk nonalcoholic steatohepatitis (NASH) in Hepatology Communications1. In conjunction with Labcorp, a global leader of
